Key facts
- Enemsa Pharma’s last known valuation is $1.1M (Dec 2025).
- It has raised $290K; the latest was Seed Round ($290K) in Dec 2025.
- Notable investors include Remiges Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Enemsa Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Enemsa Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enemsa Pharma
Developer of small-molecule therapeutics designed to treat neurodegenerative diseases. The company develops oral compounds targeting conditions such as amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, and Parkinson's disease, enabling advancement of therapies that support neuronal survival and reduce disease progression.
- Sector
- Healthcare
- HQ
- Nantes, France
- Founded
- 2025
- Ownership
- Privately Held (backing)
Enemsa Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enemsa Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enemsa Pharma in its N-PORT filings yet. We sweep new filings monthly.